Breast cancer

Gene expression test EndoPredict predicts local recurrences

(DGAP-Media / 08.04.2015 / 14:23)

The gene expression test EndoPredict(R) not only determines the probability
of metastases of breast cancer, but also describes the risk of a local
recurrence in the breast. This is the result of an analysis of the ABCSG-8
study of the Austrian Breast and Colorectal Cancer Study Group. The results
were recently published in the British Journal of Cancer.

1324 patients with hormone receptor positive/HER2-negative breast cancer
were assigned to a low- or to a high-risk group using the EndoPredict test.
A retrospective analysis of the disease courses over a period of ten years
demonstrated that 97.5% of the low-risk patients remained free from local
recurrences. In high-risk patients, the survival without local recurrences
was only 91%.

"The knowledge about the increased risk of local recurrence of breast
cancer is particularly relevant for follow-up care", explained Univ.-Prof.
Dr. Florian Fitzal, author of the publication , head of the Breast Health
Centre in Linz (AUT) and member of the Cancer Comprehensive Center of
Vienna Medical University. "Irrespective of the risk of local recurrence,
the best local therapy is either a mastectomy or breast-conserving surgery
with subsequent radiation."

EndoPredict measures the activity of altogether eight disease-relevant
genes. The test is used in routine medical practice to clarify whether a
patient requires chemotherapy, or whether this burdensome therapy can be
foregone due to the patient's low risk of recurrence. The test is
recommended, amongst others, in the guidelines of the Association of
Gynaecological Oncology (AGO) and by the experts of the St. Gallen
consensus conference.


Sividon Diagnostics GmbH was founded in July 2010 as a management buyout
from Siemens Healthcare Diagnostics Products in Cologne, Germany. The
company aims to sustainably increase the quality of therapy-accompanying
diagnostics in oncology. EndoPredict(R), the first diagnostic test from
Sividon, has been available since 2011.

Further information is available at www.sividon.com or www.endopredict.com.


End of Media Release

---------------------------------------------------------------------

Issuer: Sividon Diagnostics GmbH
Key word(s): Health

08.04.2015 Dissemination of a Press Release, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


342139 08.04.2015